Detailed Information

Cited 1 time in webofscience Cited 1 time in scopus
Metadata Downloads

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Koreaopen access

Authors
Shim, Tae SunPai, HelenMok, JeongHaLee, Seung HeonKwon, Yong-SooChoi, Jae CholPark, JaeSeokBirmingham, EileenMao, GaryAlquier, LoriDavis, KourtneyThoret-Bauchet, FlorenceKim, Ji HyunKim, HyeongyeongBakare, Nyasha
Issue Date
Jan-2023
Publisher
BioMed Central
Keywords
Tuberculosis; Multidrug-resistant; Bedaquiline; South Korea
Citation
BMC Infectious Diseases, v.23, no.1
Indexed
SCIE
SCOPUS
Journal Title
BMC Infectious Diseases
Volume
23
Number
1
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62406
DOI
10.1186/s12879-022-07955-6
ISSN
1471-2334
Abstract
Background Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB. Methods A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician’s discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines. Results The safety population included 172 patients (88 bedaquiline and 84 non-bedaquiline). The mean (standard deviation, SD) duration of follow-up was 24.3 (9.5) months. Mean (SD) durations of treatment were 5.4 (1.8) months in bedaquiline-treated patients and 15.7 (6.7) months in the non-bedaquiline group. Treatment success (cured and treatment completed according to WHO 2013 treatment outcome definitions) was achieved by 56.3% of bedaquiline-treated and 45.2% of non-bedaquiline-treated patients. Sputum culture conversion rates were 90.4% and 83.7% with and without bedaquiline, respectively. Diarrhoea and nausea were the most frequently reported treatment-emergent adverse events (TEAEs) in the bedaquiline group (27.3% [24/88] and 22.7% [20/88], respectively). The most frequent bedaquiline-related TEAEs were prolonged QT interval (10.2%; 9/88), and diarrhoea and nausea (9.1% each; 8/88). QT interval prolongation was reported in 19.3% (17/88) of bedaquiline-treated and 2.4% (2/84) of non-bedaquiline-treated patients, but bedaquiline was not discontinued for any patient for this reason. There were 13 (14.7%) and three (3.6%) deaths in the bedaquiline-treated and non-bedaquiline groups, respectively. Review of fatal cases revealed no unexpected safety findings, and no deaths were bedaquiline-related. The most common cause of death was worsening cancer (three patients). Patients in the bedaquiline group tended to have poorer baseline risk profiles than non-bedaquiline patients and were more likely to have relapsed or already failed second-line treatment. Interpretation of mortality data was complicated by high rates of loss to follow-up in both groups. Conclusions The South Korean registry findings support previous risk/benefit observations and the continued use of bedaquiline as part of combination therapy in patients with MDR-TB.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Pulmonary, Allergy, and Critical Care Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Seung Heon photo

Lee, Seung Heon
Ansan Hospital (Department of Pulmonary, Allergy, and Critical Care Medicine, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE